KRAS and colorectal carcinoma: We investigated the tumor suppressive effect of Calebin A on the malignity potential of three different colorectal cancer (CRC) cell lines (HCT116, SW480 and RKO), as all three cell lines are derived from primary tumors of three distinct patients (HCT116 and RKO from colorectal carcinomas and SW480 from colorectal adenocarcinoma) and exhibit different genetic features and mutations in cancer critical genes (microsatillite stability/instability, KRAS, RAF, PIk3CA and TP53) [47].